Dave Portnoy spurred a new generation of retail traders, but the Barstool Sports founder said Monday on CNBC's "Fast Money" he can't be responsible for the actions of others.'Barstooling It': The rise in retail trading activity is in part due to Portnoy branding himself as "Davey Day Trader." His newfound popularity in the trading universe is merely a function of "doing something the financial community hasn't seen before and making it fun," Portnoy said."We are 'Barstooling' it, we are making hype videos, we are getting behind it, we are live-streaming it," he said. "And I think a lot of the old-time guys just don't know what the hell is going on with us so they don't know what to make of us."See Also: Are Robinhood Retail Traders Fueling The Rally? It Depends Who You Ask'Clear What We Are': Portnoy makes it "clear what we are" and admits he has no "great knowledge" of stocks. If retail investors follow his actions and potentially lose money on a rare penny stock mention, he "can't be held responsible for total idiots."Portnoy has made some profitable trades among well-known brands, including personally buying and recommending Spirit Airlines Incorporated (NYSE: SAVE) near $8 per share. Anyone who took his advice is sitting on a hefty profit with the stock trading north of $20. The stock needs to "crash significantly for about a week straight" to erase all of the gains."People have to make decisions for themselves, obviously," he said. "If you want to jump on, you jump on. The facts are I'm not going to feel bad when I have like 400% returns since I started doing this."See Also: Dave Portnoy Trades And Entertains, But Whitney Tilson Says He's Reminiscent Of The 'Proverbial Shoeshine Boy'The Buffett Call: Billionaire investor Warren Buffett has been buying and selling stocks for decades, but Portnoy has no ambition to follow suit. He said once the COVID-19 pandemic is over, he needs to return to his "pretty busy job" at Barstool Sports.In the meantime, Portnoy said it's factually correct to say he 's outperforming Buffett after loading up on airliner stocks near the bottom: "because I am."Buffett is also pushing 90 years old so even claiming he is past his prime shouldn't be seen as an insult, Portnoy said."I have said all along, he is the greatest investor of all time," he said. "But right now, in this market, I'm doing better."Top Stock Pick: Davey Day Trader's top pick in this current environment: Smith & Wesson Brands Inc (NASDAQ: SWBI). Photo screenshot via CNBC.See more from Benzinga * Ex-SEC Chief Pitt Surprised At Investor Gullibility, Says They're Buying 'Garbage' * McDonald's Serves Up April, May Metrics, COVID-19 Update * What Data From Yelp And OpenTable Tells Us About The State Of Restaurants(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
from Yahoo Finance https://ift.tt/2N6oGWF
VMware on the list Continue reading…
Coronavirus vaccine maker Moderna Inc (NASDAQ: MRNA) is closing in on the final stages of its vaccine program and could have the efficacy data by Thanksgiving, paving the way for a potential Emergency Use Authorization approval by the FDA, Bloomberg reported, citing an interview with the company's CEO Stephane Bancel.What Happened: Moderna's coronavirus vaccine, codenamed mRNA-1273, is in Phase 2 testing and could yield efficacy data as early as Thanksgiving if everything goes right, Bancel told Bloomberg. The CEO also discussed about the possibility of the FDA according EUA at high risk."They might decide to give us emergency use approval for people at very high risk, while the agency more carefully reviews the data before granting approval for a broader population, " Bancel said.Moderna is measuring whether the vaccine prevents COVID-19 or potentially prevents infection, she said. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Working On Pricing: Moderna's CEO also suggested in the interview the company is working on how best to price a coronavirus vaccine to make it both affordable and viable for the company. "What we need to make sure is that the vaccine is affordable. But vaccines won't be free," Bancel said. Moderna is scheduled to start a Phase 3 trial evaluating about 30,000 volunteers, in Jul while the NIAID-sponsored Phase 1 trial and the company-managed Phase 2 trial are ongoing.Preliminary results from the Phase 1 study released in mid-May demonstrated positive immunogenicity and safety.MRNA Price Action: The stock was down 5.27% at $63.06 at the time of publication. Related Links:Moderna Analyst Says Coronavirus Vaccine Candidate Has 65% Chance Of Success Coronavirus Vaccine Frontrunner Moderna Appoints Former Amgen Executive As CFO See more from Benzinga * Moderna Closing In On Deal To Supply Coronavirus Vaccine To Israel: Report * Sinovac Makes Headway In Coronavirus Vaccine Race With Positive Preliminary Phase 1/2 Results * Moderna On Track To Start Phase 3 Coronavirus Vaccine Trial In July(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.